​​
Expanding Pharmaceutical Horizons
 

​​
Founded by a management team with a solid track record for delivering outcomes, Boston Arcadia employs a practical, results oriented approach to deliver pharmaceuticals with geographically, strategically and financially expanded horizons. It does this both for its own programs and leverages the same expertise to deliver results for its clients.

Boston Arcadia is built on a foundation of decades of hands-on experience from within the US and European for-profit, and not-for-profit pharmaceutical and drug development industries. Leveraging broad contacts and expertise across these environments, Boston Arcadia focuses on three core areas to deliver both its own and client programs: 

  • Drug Development: This encompasses the licensing of pharmaceutical assets, coordinating the generation of pre-clinical and clinical data, and drug registration. Boston Arcadia’s sweet-spot is leveraging existing non-US pharmaceutical dossiers, and re-casting them for product registration with the FDA and EMA. This can be either within the existing drug label, or within niched associated indications, particularly within the US market. 
  • Strategic Consultancy: From first-hand experience across multiple organizations, Boston Arcadia crafts tailored, practical, and implementable strategies with a sweet spot in delivering therapeutic area strategies for a public mid cap and private biotech client base. 
  • Non-Dilutive Financing: Boston Arcadia accesses non-dilutive pharmaceutical development funding for its own, and its clients programs through two proven routes. Firstly, via classical business development with pharma and biotech strategic partners, based on a rolodex spanning decades of industry contacts, pitch, negotiation and alliance management expertise. Secondly, by tapping into the extensive array of applicable US governmental pharmaceutical innovation funding resources. Boston Arcadia’s sweet spot is coordinating with expert US fund raising organizations, to formulate, target and prosecute non-dilutive product funding opportunities. 
    ​